Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4702985 | 0.88 | AAK1 (0.32) | AAK1 | |
| SCHEMBL20711956 | 0.85 | AAK1 (0.35) | AAK1MMP13HDAC1HDAC2HDAC6 | |
| SCHEMBL15845208 | 0.85 | MMP13 (0.38) | AAK1MMP13HDAC1HDAC2HDAC6 | |
| SCHEMBL15845207 | 0.85 | MMP13 (0.38) | AAK1MMP13HDAC1HDAC2HDAC6 | |
| SCHEMBL14842413 | 0.83 | AAK1 (0.38) | AAK1MMP13HDAC1HDAC2HDAC6 | |
| SCHEMBL12183575 | 0.83 | AAK1 (0.38) | AAK1MMP13HDAC1HDAC2HDAC6 | |
| SCHEMBL850510 | 0.81 | AAK1 (0.38) | AAK1MMP13HDAC1HDAC2HDAC6 | |
| SCHEMBL7286419 | 0.80 | AAK1 (0.50) | AAK1MMP13HDAC1HDAC2HDAC6 | |
| SCHEMBL11194156 | 0.78 | HDAC6 (0.30) | HDAC6 | |
| SCHEMBL20202843 | 0.78 | KIF11 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633729-B1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20060122195-A1 | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122195-A1 | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | CCR4, CCR1, CCR3 | AAK1 3666/4885MMP13 2139/4885HDAC1 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.